ADRX SCHEDULE 13G: SEC filing
Zhen Li
Filed with the SEC on · accession 0001729510-26-000009
ADRX filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 13, 2026. A report the company filed with the SEC (the US market regulator). The stock moved -4.8% by the first close after the filing.
Summary of the filing
Zhen Li filed a Schedule 13G reporting beneficial ownership of approximately 9.7% of ADARx Pharmaceuticals, consisting of exercisable options and shares held through the Titanium Trust.
Key details
How ADRX stock reacted
Close before
$14.91
Nov 12, 2026
First close after
-4.76%
$14.20
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for ADRX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ADRX?
Click hereFrequently asked questions
What did ADRX file with the SEC on Nov 13, 2026?
ADRX filed a SCHEDULE 13G (SEC filing). Zhen Li filed a Schedule 13G reporting beneficial ownership of approximately 9.7% of ADARx Pharmaceuticals, consisting of exercisable options and shares held through the Titanium Trust.
How do I read a SCHEDULE 13G?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).
How did ADRX stock react to this filing?
ADRX closed at $14.91 before the filing and $14.20 on Nov 13, 2026 (-4.76%).
Other ADRX SEC filings
Get alerts when ADRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days